

EARNINGS RELEASE 3Q | 2024

07.november.2024





Contents



1.	Highlights.....	2
2.	Revenues.....	5
3.	Costs and Expenses.....	7
4.	EBIT e EBITDA.....	9
5.	Net Financial Result.....	10
6.	Net Income/(Loss).....	11
7.	Debt and Leverage	12
8.	Cash Flow	13



Earnings Video Conference
November, 08th 2024 (friday)
09am Brasília | 08am EST



Zoom Webcast in Portuguese
(Simultaneous translation to English)

HIGHLIGHTS

Belo Horizonte, November 07th, 2024 - **Rede Mater Dei de Saúde** (“Mater Dei” or “Company”) (B3: MATD3) announces its results for the third quarter of 2024 (3Q24). The financial statements presented in this report refers to the consolidated figures in Reais (BRL) million, except when otherwise indicated. The comparisons are made with the third quarter of 2023 (YoY comparison) and the second quarter of 2024 (QoQ comparison). The quarter information follows the Brazilian and International (IFRS) accounting rules and were revised by independent auditors.

Centro de Saúde Norte Divestment

On September 16th, 2024, was concluded the divestiture of its corporate interest equal to 70% of Centro Saúde Norte S.A. (“CSN”) capital stock, Hospital Porto Dias holdings, in exchange Mater Dei received BRL 401.3 million in local currency and 27,272,728 shares issued by the Company, of which 24,660,627 shares were cancelled.


For the quarter, the presented results are consolidated with CNS results until the divestment closing date, except when indicated.

The Operation strengthens the Company’s financial discipline, through a portfolio adjustment in a challenging moment for the sector, decreasing its exposition to risk and boosting its cash position with an considerable improvement in receivables, working capital and capital structure of the Company.



Operational and Financial Highlights

- ✚ **Occupancy rate:** growth of 3.2pp YoY and drop of 2.8pp QoQ, reaching 72.8% in the quarter. If patient Day Hospital are taken in account, this rate reaches 76.5%;
- ✚ **Patient-day:** stable compared with third quarter of 2023 and decrease of 7% against last quarter. In the nine months comparison, there was a growth of 7%;
- ✚ **Average Ticket:** reached BRL 2.30 million per used bed in the quarter, align with 3T23 and growth of 5% compared to second quarter of 2024. Disregarding the Porto Dias' result in the quarter, the average ticket reached BRL 2.41 million against BRL 2.31 million in previous quarter, growth of 4%;
- ✚ **Net Debt:** of BRL 710 million, with a debt cost below CDI and **leverage index** of 1.3x (financial net debt /EBITDA LTM);
- ✚ **Net revenue:** totaled BRL 571 million in the quarter, stable against last year and a decrease of 3% QoQ. For the year to date reached BRL 1.739 million, 6% higher than last year;
- ✚ **Adjusted EBITDA:** as shown in the chart below, the EBITDA adjusted for the sale of Porto Dias in 3Q24 reached R\$ 191 million, with a margin of 33.5%, and after other operational adjustments, it totaled R\$ 121 million, with an adjusted margin of 21.3%. In the nine months, the EBITDA adjusted for the sale reached R\$ 450 million, with a margin of 25.9%, and after other adjustments, it totaled R\$ 381 million, with a margin of 21.9%.



BRL Million (except when indicated)	3Q24	3Q23	Δ 3Q24	2Q24	Δ 3Q24	9M24	9M23	Δ 9M24
Operational Indicator								
Operational Beds (average of the period)	1,532	1,590	(3.7%)	1,602	(4.4%)	1,556	1,565	(0.6%)
Patients-day (total of the period)	102,565	101,809	0.7%	110,242	(7.0%)	323,286	303,537	6.5%
Occupancy rate (average of the period)	72.8%	69.6%	3.2pp	75.6%	(2.8pp)	75.8%	71.0%	4.8pp
Financial Indicator								
Average Ticket (BRL mm / bed)	2.30	2.32	(0.6%)	2.20	4.6%	2.23	2.22	0.3%
Net Revenue	570.8	568.2	0.5%	585.3	(2.5%)	1,739.0	1,646.4	5.6%
Gross Profit	173.6	185.5	(6.4%)	174.9	(0.8%)	541.6	549.1	(1.4%)
<i>Gross Margin</i>	30.4%	32.6%	(2.2pp)	29.9%	0.5pp	31.1%	33.4%	(2.3pp)
Adjusted EBITDA	121.3	134.3	(9.6%)	120.3	0.8%	381.2	413.1	(7.7%)
<i>Adjusted EBITDA Margin</i>	21.3%	23.6%	(2.3pp)	20.6%	0.7pp	21.9%	25.1%	(3.2pp)

Highlights

Opening of Nova Lima unit

On August 23rd, 2024, the fourth unit of the Company in the metro region of Belo Horizonte opened, strategic located in Nova Lima, the new unit has capacity for 117 beds and offers a broad range of medical specialties, including a 24-hours pediatric, adult and obstetric emergency room, a diagnostic medicine service, an infusion center and clinical and surgical admission. The structure of the new unit was developed to a high standard of hospital architecture, providing comfort, safety and quality care, with internationally certified hospital processes.



Clinical Excellence Yearbook



For the second year running, Rede Mater Dei disclosure its Clinical Excellence Yearbook, a document that presents the Company’s results for 2023 and brings clinical indicators compared with the data released by the National Association of Private Hospitals (ANAHP) in the same year. The report data were audited by an external source and reinforces the excellence in patient care and safety that the Rede Mater Dei cherishes.

The document shows how Mater Dei has achieved above-average results in treatments for sepsis, oncology, heart attacks, strokes, maternal and childcare, among many other indicators. [Click on the image to access the document.](#)

The publication was launched at CONAHP 2024 (National Congress of Private Hospitals) in October. At the event, Mater Dei was also awarded a prize in the poster session for its work with the Uberlândia team: “Transformation in Patient Safety and Sustainability: Impactful Results of the Antimicrobial Stewardship Program at Mater Dei Santa Clara Hospital”.

Sustainability Report

Rede Mater Dei released in July its fifth Sustainability Report, reinforcing its commitment to the ESG aspect (environmental, social and governance). The annual publication aims to present data and information relating to the sustainability and governance initiatives carried out by Mater Dei, considering data for 2023. The report was drawn up following the international guidelines established by the GRI (Global Reporting Initiative).

Rede Mater Dei remains engaged in its commitments, goals and objectives, promoting internal actions and innovative projects that make it possible to deliver business indicators.

The report is available on the Company's Investor Relations website.




REVENUES

Gross revenue consists mainly of health services, such as admissions, surgeries, oncology, medical appointments, and laboratory tests, among others, either through healthcare operators, self- management and autarchy or out-of-pocket patients.


In the third quarter of 2024, the **average** number of operational beds reached 1,532, a drop of 58 beds against 3Q23 and of 70 beds QoQ, with an occupancy rate of 72.8%, this decrease in the number of beds is mainly explained, by the exit of Hospital Porto Dias in September. The occupancy rate calculation only considers the patients who stay overnight in the hospitals. If Day Patients, those who stay in the hospital for a period of 6 hours or less, were considered, the occupancy rate would increase to 76.5%.

Quarterly evolution of the average operational beds and occupancy rate




In the third quarter, the volume of patients day hospitalized at Rede Mater Dei increased 0.7% when compared to 3Q23. If the number of patients day did not consider the Porto Dias results, there would be an increase of 5.4% year over year.

% change in number of patients day vs. 3Q23



The consolidated average ticket for the third quarter stayed stable compared to 3Q23 and increased 4.6% against 2Q24, reaching BRL 2.30 million per used bed. The composition of the ticket is explained by: (i) hospital mix in the consolidation, (ii) mix of services and procedures; (iii) accreditation portfolio, and (iv) readjustment of the price list with payors. The average ticket variation for the quarter is explained mainly due to the mix of services and procedures.



In 3Q24, the gross revenue reached BRL 645 million, stable compared to 3Q23 and a drop of 2.7% compared to 2Q24. In the nine first months of 2024, the gross revenue totaled BRL 1,970 million, an increase of 7% compared to the same period of 2023. The gross revenue is deducted, mainly, by: (i) medical disallowances, (ii) taxes levied on gross revenue (federal contributions and municipal contributions) and (iii) cancellations.

In the third quarter of 2024, net revenue totaled BRL 571 million, stable in the annual comparison and a decrease of 3% versus 2Q24. In the year to date, net revenue totaled BRL 1,739 million, a growth of 6% against the first nine months of 2023.

BRL Million	3Q24	3Q23	Δ 3Q24	2Q24	Δ 3Q24	9M24	9M23	Δ 9M24
Healthcare operators	596.4	596.1	0.0%	612.1	(2.6%)	1,822.0	1,719.5	6.0%
Out-of-pocket patients	40.2	39.2	2.8%	42.3	(4.8%)	121.7	105.6	15.2%
Other revenues	8.7	9.1	(4.3%)	8.8	(1.2%)	25.9	23.9	8.3%
Gross Revenue	645.4	644.4	0.1%	663.2	(2.7%)	1,969.5	1,849.1	6.5%
Medical Disallowances	(32.8)	(32.5)	0.9%	(34.7)	(5.5%)	(102.5)	(82.8)	23.7%
Tax and deductions	(41.8)	(43.7)	(4.4%)	(43.2)	(3.3%)	(128.0)	(119.8)	6.9%
Net Revenue	570.8	568.2	0.5%	585.3	(2.5%)	1,739.0	1,646.4	5.6%

COSTS AND EXPENSES

Cost of services provided

The costs of services provided mainly include medical supplies and drugs, personnel, physicians, depreciation and amortization, and maintenance and conservation.

In 3Q24, the costs of services provided totaled BRL 397 million, representing 69.6% of net revenues, an increase of 2.2pp in the annual comparison and a decrease of 0.5pp against 2Q24.

For the period of 9M24, the cost represented 68.9% of the net revenue, a growth of 2.3pp compared to the same period of last year. In the annual comparison, both in quarterly and half-year approach, the personnel was the highest line, explained by the collective raises implemented by the Company over the year, including, mainly, the nurses minimum wage and its consequences in strategic measures adopted by the Company.

<i>BRL Million</i>	3Q24	3Q23	Δ 3Q24	2Q24	Δ 3Q24	9M24	9M23	Δ 9M24
Medical Supplies and Drug	(135.7)	(135.4)	0.2%	(148.2)	(8.4%)	(417.4)	(395.9)	5.4%
<i>% of net revenue</i>	23.8%	23.8%	-	25.3%	(1.5pp)	24.0%	24.0%	-
Personnel	(119.6)	(108.7)	10.0%	(116.4)	2.7%	(348.4)	(306.0)	13.8%
<i>% of net revenue</i>	20.9%	19.1%	1.8pp	19.9%	1.0pp	20.0%	18.6%	1.4pp
Medical services	(68.9)	(67.5)	2.1%	(67.1)	2.7%	(203.6)	(185.6)	9.7%
<i>% of net revenue</i>	12.1%	11.9%	0.2pp	11.5%	0.6pp	11.7%	11.3%	0.4pp
Maintenance and conservation	(24.5)	(22.3)	10.3%	(27.0)	(9.1%)	(77.0)	(64.0)	20.3%
<i>% of net revenue</i>	4.3%	3.9%	0.4pp	4.6%	(0.3pp)	4.4%	3.9%	0.5pp
Depreciation and amortization	(21.4)	(20.6)	4.1%	(21.8)	(1.9%)	(65.1)	(61.7)	5.6%
<i>% of net revenue</i>	3.8%	3.6%	0.2pp	3.7%	0.1pp	3.7%	3.7%	-
Other costs	(27.1)	(28.3)	(4.0%)	(29.9)	(9.4%)	(85.8)	(84.1)	2.0%
<i>% of net revenue</i>	4.8%	5.0%	(0.2pp)	5.1%	(0.3pp)	4.9%	5.1%	(0.2pp)
Costs of services provided	(397.2)	(382.7)	3.8%	(410.5)	-3.2%	(1,197.4)	(1,097.3)	9.1%
<i>% of net revenue</i>	69.6%	67.4%	2.2pp	70.1%	(0.5pp)	68.9%	66.6%	2.3pp
Gross Margin	173.6	185.5	(6.4%)	174.9	(0.8%)	541.6	549.1	(1.4%)
<i>% of net revenue</i>	30.4%	32.6%	(2.2pp)	29.9%	0.5pp	31.1%	33.4%	(2.3pp)

In these terms, the gross margin totaled 30.4%, with a gross profit of BRL 174 million in 3Q24, representing a decrease of 2.2pp against 3Q23.

General expenses, administrative and others

General and administrative expenses consist mainly of personnel, depreciation and amortization, and other expenses related to back-office and integration activities.

In 3Q24, the relevance of general and administrative expenses over net revenue reached 14.0%, 0.6pp higher compared to the same period last year and 0.8pp against 2Q24. In relation to adjusted net operating expenses, that includes mainly provisions/reversals for legal demands, provisions for doubtful debts and equity pickup, there was a decrease, compared to the 3Q23 and the 2Q24, explained by a reversal in labor contingencies in the amount of BRL 74 million. Adjusting this line and the net result from the divestment of assets (recognition of a loss in the amount of BRL 754 million with the reversal of BRL 744 million recognized in the previous quarter), there was an increase of 1.2pp compared to 3Q23 and of 0.5pp compared to 2Q24.

For the nine-month period, the adjusted expenses represented 14.2% of net revenue, a growth of 1.3pp in comparison with the same period last year, impacted by provision for contingencies and provisions for doubtful debts (revenue cycle).

BRL Million	3Q24	3Q23	Δ 3Q24	2Q24	Δ 3Q24	9M24	9M23	Δ 9M24
Personnel	(50.5)	(48.2)	4.8%	(50.5)	0.0%	(147.3)	(139.4)	5.7%
<i>% of net revenue</i>	8.8%	8.5%	0.3pp	8.6%	0.2pp	8.5%	8.5%	-
Depreciation and amortization	(5.8)	(4.9)	18.6%	(5.7)	2.5%	(17.0)	(14.3)	18.8%
<i>% of net revenue</i>	1.0%	0.9%	0.1pp	1.0%	-	1.0%	0.9%	0.1pp
Third-party services	(15.3)	(15.6)	(1.6%)	(14.6)	5.2%	(44.4)	(45.2)	(1.8%)
<i>% of net revenue</i>	2.7%	2.7%	-	2.5%	0.2pp	2.6%	2.7%	(0.1pp)
Other expenses	(8.3)	(7.6)	9.1%	(6.3)	31.5%	(20.8)	(21.3)	(2.5%)
<i>% of net revenue</i>	1.5%	1.3%	0.2pp	1.1%	0.4pp	1.2%	1.3%	(0.1pp)
General and Adm. Expenses	(79.9)	(76.2)	4.8%	(77.0)	3.8%	(229.5)	(220.3)	4.2%
<i>% of net revenues</i>	14.0%	13.4%	0.6pp	13.2%	0.8pp	13.2%	13.4%	(0.2pp)
Other Operational Rev. and Exp.	60.0	(0.5)	(12,301.4%)	(6.0)	(1,095.9%)	(698.5)	8.3	(8,523.1%)
<i>% of net revenue</i>	-10.5%	0.1%	(10.6pp)	1.0%	(11.5pp)	40.2%	-0.5%	40.7pp
Net operating expenses	(19.9)	(76.7)	(74.1%)	(83.1)	(76.0%)	(928.1)	(212.0)	337.8%
<i>% of net revenue</i>	3.5%	13.5%	(10.0pp)	14.2%	(10.7pp)	53.4%	12.9%	40.5pp
Divestment of assets	10.1	-	-	-	-	754.3	-	-
Contingencies reversal	(74.0)	-	-	-	-	(74.0)	-	-
Adjusted net operating expenses	(83.8)	(76.7)	9.2%	(83.1)	0.8%	(247.8)	(212.0)	16.9%
<i>% of net revenue</i>	14.7%	13.5%	1.2pp	14.2%	0.5pp	14.2%	12.9%	1.3pp

EBIT and EBITDA

In the second quarter of 2024, the Centro Saúde Norte divestment was carried forward the Company's result as an accounting provision in the negative value of BRL 744 million in the impairment of assets line. With the conclusion of the operation in September 2024 there was a reversal of this value in the other operational revenue and expenses line and a recognition of a negative value of BRL 754 million also in this line. To help with the comparisons, for being a non-recurring effect and that not affect cash, we present the EBITDA adjusted with this difference between the provision and the final entry. It was also adjusted two other effects, (i) BRL 4,3 million referring to Nova Lima's preoperational values, unit that was opened in the end of August 2024, and (ii) the reversal in labor contingencies in the value of BRL 74 million, based on recent rulings by higher courts that doctors are not employed by hospitals.

Adjusted EBITDA in the quarter reached BRL 121 million, lower 10% against 3Q23 and stable compared to 2Q24. The adjusted EBITDA margin reached 21.3%, this result represents a decrease of 2.3pp compared to 3Q23 and an increase of 0.7pp versus 2Q24. In the 9M24 period, adjusted EBITDA reached BRL 381 million with a margin of 21.9%.

BRL Million	3Q24	3Q23	Δ 3Q24	2Q24	Δ 3Q24	9M24	9M23	Δ 9M24
Gross Revenue	645.4	644.4	0.1%	663.2	(2.7%)	1,969.5	1,849.1	6.5%
Tax, deductions and disallowances	(74.6)	(76.2)	(2.2%)	(77.9)	(4.2%)	(230.6)	(202.6)	13.8%
Net Revenue	570.8	568.2	0.5%	585.3	(2.5%)	1,739.0	1,646.4	5.6%
Costs of services provided	(397.2)	(382.7)	3.8%	(410.5)	(3.2%)	(1,197.4)	(1,097.3)	9.1%
Net operating expenses	(19.9)	(76.7)	(74.1%)	(83.1)	(76.0%)	(928.1)	(212.0)	337.8%
Impaired asset	-	-	-	(744.1)	-	-	-	-
EBIT	153.7	108.8	41.3%	(652.3)	(123.6%)	(386.5)	337.1	(214.7%)
<i>% of net revenue</i>	<i>26.9%</i>	<i>19.1%</i>	<i>7.8pp</i>	<i>-111.4%</i>	<i>138.3pp</i>	<i>-22.2%</i>	<i>20.5%</i>	<i>(42.7pp)</i>
Depreciation and amortization	27.2	25.5	6.9%	27.5	(1.0%)	82.2	76.0	8.1%
EBITDA	180.9	134.3	34.8%	(624.8)	(129.0%)	(304.3)	413.1	(173.7%)
<i>% of net revenue</i>	<i>31.7%</i>	<i>23.6%</i>	<i>8.1pp</i>	<i>-106.7%</i>	<i>138.4pp</i>	<i>-17.5%</i>	<i>25.1%</i>	<i>(42.6pp)</i>
Divestment of assets / Impairment of assets	10.1	-	-	744.1	(98.6%)	754.3	-	-
Nova Lima preoperational	4.3	-	-	1.0	333.7%	5.3	-	-
Contingencies reversal	(74.0)	-	-	-	-	(74.0)	-	-
Adjusted EBITDA	121.3	134.3	(9.6%)	120.3	0.8%	381.2	413.1	(7.7%)
<i>% of net revenue</i>	<i>21.3%</i>	<i>23.6%</i>	<i>(2.3pp)</i>	<i>20.6%</i>	<i>0.7pp</i>	<i>21.9%</i>	<i>25.1%</i>	<i>(3.2pp)</i>

NET FINANCIAL RESULT

In the quarter, net financial result reached negative BRL 32 million, against negative BRL 56 million in 2Q23, this improvement comes mainly from the reversal of the monetary update of contingency in the value of BRL 16,4 million and negative BRL 47 million in 1Q24.

In the year to date, net financial result was negative BRL 128 million, a drop of 25% against 9M23. This improvement is also related to the line of interest on loans, financing, installment and acquisitions, with a lower interest rate.

<i>BRL Million</i>	3Q24	3Q23	Δ 3Q24	2Q24	Δ 3Q24	9M24	9M23	Δ 9M24
Financial Revenue	34.1	14.4	137.1%	14.0	143.3%	62.0	40.7	52.1%
Financial Expense	(66.0)	(70.3)	(6.1%)	(60.7)	8.8%	(189.7)	(210.7)	(9.9%)
<i>Interest on loans, financing, installment and acquisitions</i>	(39.2)	(38.3)	2.3%	(34.3)	14.4%	(110.3)	(124.1)	(11.1%)
<i>Lease interest</i>	(21.7)	(20.9)	3.6%	(21.9)	(0.9%)	(65.2)	(62.3)	4.6%
<i>Others</i>	(5.1)	(11.0)	(53.9%)	(4.5)	12.9%	(14.2)	(24.2)	(41.4%)
Net Financial Result	(31.9)	(55.9)	(43.0%)	(46.6)	(31.7%)	(127.8)	(169.9)	(24.8%)

NET INCOME/(LOSS)

In this quarter, adjusted net income totaled BRL 56 million, an increase of 6% compared to the same period last year and of 9% compared to 2Q24. The adjusted net margin hit 9.8% this quarter, representing an increase of 0.4pp in the annual comparison and of 1.0pp in the quarterly comparison.

The adjustment in the net income are: (i) BRL 15 million, referring to the provision for deferred income tax liabilities on amortization of goodwill in the Parent Company until the closing date (with the closing of the operation, this benefit white off) and (ii) the same adjustments of EBITDA discounted the Income Tax and Social Contribution rate.

For the year to date, adjusted net income reached BRL 172 million, a growth of 3% in the annual comparison, with an adjusted net income of 9.9%.

<i>BRL Million</i>	3Q24	3Q23	Δ 3Q24	2Q24	Δ 3Q24	9M24	9M23	Δ 9M24
EBIT	153.7	108.8	41.3%	(652.3)	(123.6%)	(386.5)	337.1	(214.7%)
Net financial result	(31.9)	(55.9)	(43.0%)	(46.6)	(31.7%)	(127.8)	(169.9)	(24.8%)
EBT	121.8	52.9	130.4%	(698.9)	(117.4%)	(514.3)	167.2	(407.6%)
Income tax and Social Contribution	(41.3)	(17.6)	134.0%	240.4	(117.2%)	182.2	(54.4)	(434.8%)
Net Income	80.5	35.2	128.6%	(458.5)	(117.6%)	(332.1)	112.8	(394.5%)
<i>% of net revenue</i>	<i>14.1%</i>	<i>6.2%</i>	<i>7.9pp</i>	<i>-78.3%</i>	<i>92.4pp</i>	<i>-19.1%</i>	<i>6.8%</i>	<i>(25.9pp)</i>
Deferred Income tax (goodwill)	15.0	17.9	(16.3%)	18.2	(17.4%)	51.1	53.8	(5.0%)
Divestment of assets / Impairment of assets	6.7	-	-	491.1	(98.6%)	497.8	-	-
Nova Lima preoperational	2.8	-	-	0.7	333.7%	3.5	-	-
Contingencies reversal	(48.8)	-	-	-	-	(48.8)	-	-
Adjusted Net Income	56.2	53.2	5.7%	51.4	9.4%	171.5	166.6	3.0%
<i>% of net revenue</i>	<i>9.8%</i>	<i>9.4%</i>	<i>0.4pp</i>	<i>8.8%</i>	<i>1.0pp</i>	<i>9.9%</i>	<i>10.1%</i>	<i>(0.2pp)</i>

DEBT AND LEVERAGE

In the third quarter of 2024, the net debt was of BRL R\$ 710 million, lower 36% than the final amount of last quarter, explained by the receipt of BRL 401 million of the CSN disinvestment.

The leverage index (financial net debt / EBITDA LTM) reached 1.3x in 3Q24, lower in 0.4x and 0.9x than in the same period of the previous year and in the previous quarter, respectively.

BRL Million	3Q24	3Q23	Δ 3Q24	2Q24	Δ 3Q24
Short-term debt	99.7	77.4	28.8%	75.8	31.5%
Long-term debt	1,356.4	1,210.2	12.1%	1,364.8	-0.6%
Derivative financial instruments (+/-) ¹	9.9	(0.3)	(3.929.3%)	8.1	22.1%
Total debt²	1,466.0	1,287.4	13.9%	1,448.8	1.2%
Cash and equivalents and financial investments	755.9	363.7	107.8%	324.6	132.9%
Cash and equivalents and financial investments of asset available to sell	-	-	-	16.4	(100.0%)
Net Debt	710.1	923.6	(23.1%)	1,107.8	(35.9%)
EBITDA LTM ³	563.1	534.9	5.3%	505.5	11.4%
Net debt/EBITDA (LTM)	1.3x	1.7x	(0.4)	2.2x	(0.9)


1. Derivative instrument (swap) related to the exchange of an IPCA rate to a CDI rate in the Banco do Nordeste (BNB) debt.

2. According to the covenant of the debentures issue of the Company, consider the sum of the balances of loans, financing and debentures net of all derivative financial instruments (current and non-current). It does not consider liabilities for lease and acquisition of companies payable.


3. According to the covenant of the debentures issue of the Company, EBITDA is the earnings before interest, taxes, depreciation and amortization, impaired asset and equity pickup.

Mater Dei's weighted average amortization term is 4.5 years. The cost of debt for 3Q24 was of CDI – 0,5% a year.

Debt payment schedule⁴ (BRL Mm)



Average Cost of debt and Indexation




4. Does not consider transaction cost.

CASH FLOW

Considering the position of cash, cash equivalents and financial investments, the company ended 3Q24 with BRL 756 million, a growth of 137% compared to the cash at the end of the previous year.

In the first nine months of 2024, cash generated by operations before working capital amounted BRL 416 million, with R\$ 161 million being consumed by changes in assets and liabilities (accounts payable, suppliers, inventories, among others). To complete the net cash flow generated by operating activities, we had BRL 105 million paid in interest and income tax and social contribution.

Investment activities generated BRL 172 million, of which BRL 401 million received due to the CSN disinvestment, offset by the utilization of BRL 179 million for the payment of expansion and maintenance Capex and intangible assets, mainly related to Nova Lima’s unit construction. In addition, there was an inflow of BRL 104 million in financing activities, with BRL 200 million from the 2nd debentures issue in July being the main component and lastly the generation of BRL 12 million in investment income, net of redemptions.



APPENDIX

P&L

<i>Consolidated (BRL thousand)</i>	3Q24	3Q23	2Q24	9M24	9M23
Gross Revenue	645,379	644,426	663,209	1,969,527	1,849,053
Healthcare Operator	596,398	596,143	612,081	1,821,978	1,719,533
Out-of-pocket patients	40,239	39,151	42,279	121,657	105,602
Other revenue	8,742	9,132	8,849	25,892	23,918
Taxes, Deductions and Disallowance	(74,558)	(76,199)	(77,866)	(230,564)	(202,612)
Net Revenue	570,821	568,227	585,343	1,738,963	1,646,441
Costs of services provided	(397,248)	(382,742)	(410,455)	(1,197,393)	(1,097,334)
Medical Supplies and drugs	(135,669)	(135,431)	(148,187)	(417,415)	(395,866)
Personnel	(119,559)	(108,681)	(116,418)	(348,380)	(306,001)
Medical services	(68,922)	(67,526)	(67,091)	(203,626)	(185,587)
Maintenance and conservation	(24,544)	(22,259)	(26,990)	(77,012)	(63,907)
Depreciation and amortization	(21,428)	(20,591)	(21,841)	(65,149)	(61,686)
Other costs	(27,125)	(28,254)	(29,928)	(85,811)	(84,288)
Gross profit	173,574	185,485	174,888	541,570	549,107
General and administrative expenses	(79,928)	(76,235)	(77,037)	(229,534)	(220,292)
Personnel	(50,492)	(48,157)	(50,488)	(147,316)	(139,398)
Depreciation and amortization	(5,816)	(4,905)	(5,674)	(17,004)	(14,315)
Third-party services	(15,336)	(15,580)	(14,576)	(44,428)	(45,248)
Other expenses	(8,284)	(7,593)	(6,299)	(20,786)	(21,331)
Equity pickup	(791)	17	(225)	(1,249)	2,039
Other operating income (expenses)	60,823	(509)	(5,803)	(697,282)	6,254
Impairment of assets- CPC 31	-	-	(744,142)	-	-
Earnings before financial income and expenses	153,678	108,758	(652,319)	(386,495)	337,107
Financial revenue	34,106	14,382	14,019	61,952	40,739
Financial expenses	(65,963)	(70,260)	(60,646)	(189,723)	(210,660)
Net financial result	(31,857)	(55,878)	(46,627)	(127,771)	(169,921)
Earnings before income tax and social contribution	121,821	52,880	(698,946)	(514,266)	167,186
Income Tax and Social Contribution	(41,290)	(17,649)	240,407	182,216	(54,431)
Net Income / (Loss)	80,531	35,231	(458,539)	(332,050)	112,755
<i>Deferred Income tax (goodwill)</i>	15,000	17,931	18,162	51,116	53,793
<i>Divestment of assets / Impairment of assets</i>	6,681	-	491,134	497,815	-
<i>Nova Lima preoperational</i>	2,824	-	651	3,475	-
<i>Contingencies reversal</i>	(48,824)	-	-	(48,824)	-
Adjusted net income	56,212	53,162	51,408	171,532	166,548
Net income attributed to controlling partners	75,366	28,548	(464,267)	(346,720)	93,853
Net income attributed to noncontrolling partners	5,165	6,683	5,728	14,670	18,902

<i>Consolidated (BRL thousand)</i>	3Q24	3Q23	2Q24	9M24	9M23
EBIT	153,678	108,758	(652,319)	(386,495)	337,107
Depreciation and amortization	27,250	25,496	27,515	82,153	76,001
EBITDA	180,928	134,254	(624,804)	(304,342)	413,108
<i>Nova Lima preoperational</i>	4,278	-	986	5,265	-
<i>Divestment of assets / Impairment of assets</i>	10,122	-	744,142	754,264	-
<i>Contingencies reversal</i>	(73,975)	-	-	(73,975)	-
Adjusted EBITDA	121,353	134,254	120,324	381,212	413,108

Balance Sheet

<i>Consolidated (BRL thousand)</i>	09/30/2024	09/30/2023	12/31/2023
Asset			
Current			
Cash and Cash Equivalents	704,454	265,675	227,302
Financial Investments	51,460	98,061	91,831
Accounts receivable	653,957	790,725	798,581
Inventories	48,183	60,297	63,165
Derivatives	-	259	1,054
Construction Reimbursement	40,703	39,021	38,143
Construction assets to be deployed	-	4,875	-
Other current assets	45,777	49,982	38,097
Total current assets	1,544,534	1,308,895	1,258,173
Non-current			
Construction Reimbursement	295,099	301,622	305,142
Judicial deposits	50,192	68,260	48,138
Deferred taxes	231,274	48,705	58,127
Derivatives	-	-	9,800
Investments	15,773	18,867	18,812
Right of use	662,899	759,846	753,232
Fixed Assets	835,309	719,793	764,594
Intangible assets	728,753	1,851,174	1,853,209
Other non-current assets	49,766	95,210	102,224
Total non-current assets	2,869,065	3,863,477	3,913,278
Total Assets	4,413,599	5,172,372	5,171,451
Liabilities			
Current			
Suppliers	116,705	128,333	148,701
Loans and financing	99,719	77,414	52,205
Derivatives	984	-	-
Leasing	65,654	79,656	81,228
Salaries & social security contribution	82,570	108,397	74,904
Taxes and contributions payable	18,890	39,986	37,288
Installment payment of taxes	6,960	3,449	6,644
Accounts payable of company acquisition	37,236	37,351	36,931
Dividends payable	-	3,108	36,221
Other current liabilities	8,861	10,769	11,453
Total current liabilities	437,579	488,463	485,575
Non-current			
Loans and financing	1,356,412	1,210,208	1,202,660
Derivatives	8,934	-	-
Leasing	676,120	763,127	762,274
Redemption liability	80,778	410,824	422,171
Installment payment of taxes	78,093	9,088	4,695
Deferred taxes liabilities	930	84,666	99,715
Accounts payable of company acquisition	156,223	169,528	174,778
Provision for contingencies	105,131	264,156	255,417
Other non-current liabilities	12,058	9,106	9,942
Total non-current liabilities	2,474,679	2,920,703	2,931,652
Equity Capital			
Capital	1,301,019	1,301,019	1,301,019
Capital reserves	(103,253)	467,045	376,142
Income reserves	396,325	306,120	397,054
(-) Treasury stocks	(30,119)	(1,962)	(1,962)
Equity valuation adjustment	(90,705)	(409,954)	(417,112)
Total equity attributable to the Company's shareholder	1,473,267	1,662,268	1,655,141
Share of noncontrolling shareholders	28,074	100,938	99,083
Total Shareholders' equity	1,501,341	1,763,206	1,754,224
Total Liabilities	4,413,599	5,172,372	5,171,451

Cash Flow

<i>Consolidated (BRL thousand)</i>	9M24	9M23
Cash flow from operating activities		
Net profit for the period	(332,050)	112,755
Adjustments to reconcile net income to cash from operations		
Depreciation and amortization	82,153	76,001
Write-off of fixed and intangible assets	3,062	2,822
Establishment (reversal) of allowance for doubtful accounts	20,024	8,771
Establishment (reversal) of provision for disallowances	28,398	36,351
Establishment (reversal) of provision and restatement for contingencies	-85,023	5,648
Share-Based Payment provision	6,552	8,754
Equity pickup gains	1,249	(2,039)
Derivative gains	(581)	4,443
Income from financial investments	(22,276)	(23,182)
Net financial expenses	159,973	177,525
Establishment of Installment payment of taxes	938	-
Loss of impairment of assets	754,264	-
Provision for income tax and social contribution - current & deferred	(200,670)	19,164
	416,013	427,013
Variations in Operating Assets and Liabilities		
Accounts Receivable	(146,443)	(226,983)
Inventories	(505)	3,989
Other assets	2,816	(4,373)
Judicial deposits	(3,358)	(9,922)
Suppliers	(5,796)	(13,191)
Salaries and social security contributions	25,640	37,858
Taxes and contributions payable	12,196	41,012
Tax installments	(5,150)	(4,454)
Variations in Operating Assets from alienated assets	(39,995)	-
Other liabilities	(1,293)	897
	(161,888)	(175,167)
Income tax and social contributions paid	(19,595)	(29,484)
Interest paid	(85,578)	(91,911)
Net cash generated by operating activities	148,952	130,451
Cash Flow of Investment activities		
Acquisition of fixed assets	(167,224)	(103,931)
Acquisition of intangible assets	(8,422)	(8,854)
Developments with construction to be deployed	(11,801)	(24,502)
Investment acquisition	(95)	388
Controlled consolidation of initial cash	(29,156)	(41,783)
Disposal of investments	388,720	-
Financial investments made, net redemptions	52,603	58,850
Net cash generate (used) in investment activities	224,625	(119,832)
Cash flow from financing activities		
Loans and financing	206,893	82,484
Payments of loans and financing	(32,261)	(23,594)
Lease payments	(28,563)	(23,056)
Derivative settlement	(237)	(2,610)
Treasury stocks	(13,839)	-
Dividends paid	(28,418)	(24,582)
Net cash generated (used) in financing activities	103,575	8,642
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	477,152	19,261
Cash and cash equivalents at the beginning of the period	227,302	246,414
Cash and cash equivalents at the end of the period	704,454	265,675
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	477,152	19,261

GLOSSARY AND OTHER INFORMATION

Glossary

- **AoP:** Average of period
- **LTM:** Last Twelve Months
- **Net Debt:** Short-term and long-term debt, net of cash, cash equivalents and short-term investments. The term "net debt" is a measure of the Company and may not be comparable with similar terms adopted by other companies.
- **IFRS 16:** As of January 1st, 2019, all companies had to adapt to the new rules of IFRS 16. With this new standard, lessees now have to recognize the asset of rights over leased assets and the liability of future payments for medium or long-term leases, including operating leases. The biggest impact we had was on the real estate lease contracts of our operational and administrative units.
- **EBITDA:** Earnings before Interest, Taxes, Depreciation and Amortization
- **EBITDA Margin:** EBITDA divided by net revenue
- **EBIT:** Earnings before Interest and Taxes
- **SELIC:** is the Brazilian economy's basic interest rate
- **CDI:** Interbank Deposit Certificate
- **IPCA:** Extended National Consumer Price Index
- **Occupancy rate:** Number of beds occupied by patients per day added up over a given period, divided by the number of beds that were operational each day added up during the same period

About Rede Mater Dei de Saúde

Rede Mater Dei de Saúde is an integrated platform that provides hospital and cancer services, being a national reference in health and the largest private hospital network in Minas Gerais. The Company has more than 2,200 beds of capacity in its 9 units located in the metropolitan region of Belo Horizonte ("MRBH"), Salvador, Uberlândia, Goiânia and Feira de Santana.

Rede Mater Dei has a clinical expertise that is recognized by patients, medical community, healthcare operators, suppliers, and relevant sectors of the Brazilian Society, and focuses on innovation and medical pioneering.

Relationship with independent auditors

In accordance with CVM Resolution CVM 162/22, we inform that our policy for hiring independent auditors considers the best governance principles, which reserve the auditor's independence, in accordance with internationally accepted criteria.

For additional Investor Relations information, please access the website: <https://ri.materdei.com.br/en/> or e-mail ri@materdei.com.br

This material contains summary information, which is not intended to be complete and should not be considered by shareholders or potential investors as an investment recommendation. Information about Mater Dei, its activities, economic and financial situation, and the risks inherent to its activities, as well as its financial statements, can be obtained on the world wide web, on the Mater Dei website (<https://ri.materdei.com.br/en/>)

MaterDei

Rede de Saúde

 MaterDei
Hospital Santo Agostinho

 MaterDei
Hospital Betim-Contagem

 MaterDei
Hospital Nova Lima

 MaterDei
Hospital Contorno

 MaterDei
Hospital Salvador

 MaterDei
Rede de Saúde



 MaterDei
Rede de Saúde



 MaterDei
Rede de Saúde



 MaterDei
Rede de Saúde



 MaterDei
Rede de Saúde



 MaterDei
Rede de Saúde



TUDO
PRA
VOCÊ
FICAR
BEM